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The quality of life and cost utility of home nocturnal and conven-
tional in-center hemodialysis.
Background. Home nocturnal hemodialysis is an intensive
form of hemodialysis, where patients perform their treatments
at home for about 7 hours approximately 6 nights a week. Com-
pared with in-center conventional hemodialysis, home noctur-
nal hemodialysis has been shown to improve physiologic pa-
rameters and reduce health care costs; however, the effects on
quality of life and cost utility are less clear. We hypothesized
that individuals performing home nocturnal hemodialysis would
have a higher quality of life and superior cost utility than in-
center hemodialysis patients.
Methods. Home nocturnal hemodialysis patients and a de-
mographically similar group of in-center hemodialysis patients
from a hospital without a home hemodialysis program under-
went computer-assisted interviews to assess their utility score
for current health by the standard gamble method.
Results. Nineteen in-center hemodialysis and 24 home noc-
turnal hemodialysis patients were interviewed. Mean annual
costs for home nocturnal hemodialysis were about $10,000
lower for home nocturnal hemodialysis ($55,139  $7651 for
home nocturnal hemodialysis vs. $66,367  $17,502 for in-
center hemodialysis, P  0.03). Home nocturnal hemodialysis
was associated with a higher utility score than in-center hemodi-
alysis (0.77  0.23 vs. 0.53  0.35, P  0.03). The cost utility
for home nocturnal hemodialysis was $71,443/quality-adjusted
life-year (QALY), while for in-center hemodialysis it was
$125,845/QALY. Home nocturnal hemodialysis was the domi-
nant strategy, with an incremental cost-effectiveness ratio
(ICER) of $45,932. The 95% CI for the ICER, and 2500
bootstrap iterations of the ICER all fell below the cost-effec-
tiveness ceiling of $50,000. The net monetary benefit of home
nocturnal hemodialysis ranged from $11,227 to $35,669.
Conclusion. Home nocturnal hemodialysis is associated with
a higher quality of life and a superior cost utility when com-
pared to in-center hemodialysis.
Key words: economic analysis, hemodialysis, home, prospective studies,
resource allocation.
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End-stage renal disease (ESRD) decreases a person’s
length and quality of life [1–3]. Indeed, patients requiring
dialysis have a quality of life worse than individuals with
recurrent breast cancer [4]. Different forms of treatment
for ESRD lead to different levels of quality of life; for
example, home hemodialysis and kidney transplantation
have been associated with a higher quality of life than
in-center hemodialysis [3, 5–13].
Daily home nocturnal hemodialysis was developed in
Toronto in 1993 [14]. Patients place themselves on dial-
ysis at night, receive treatment while they sleep, and dis-
connect themselves the following morning. A typical
home nocturnal hemodialysis treatment lasts 6 to 8 hours,
and is performed 5 to 7 nights a week. Home nocturnal
hemodialysis has been associated with improved bio-
chemistry, blood pressure, cardiac function, and sleep
patterns [15–22]. Preliminary data suggests higher qual-
ity of life for home nocturnal hemodialysis [abstract;
Brissenden JE et al, J Am Soc Nephrol 9:168A, 1999],
but no analysis of quality of life and economic utility
exists. Additionally, some authorities suggest that im-
provements in quality of life in intensively dialyzed pa-
tients is partly due to improvements in quality of life in
all dialysis patients, a claim that makes a reanalysis of
conventional hemodialysis patients worthy.
All forms of dialysis are expensive. In-center hemodi-
alysis, the most common dialysis modality in North
America, costs between $60,000 CAN and $95,000 CAN
annually per patient [23–27]. Hospital-based treatments
are generally more expensive than home-based treat-
ments ($88,585 CAN for in-center hemodialysis vs.
$26,048 CAN for home conventional hemodialysis) [24].
Moreover, the Toronto experience demonstrates lower
costs for home nocturnal hemodialysis than in-center
hemodialysis ($56,394 CAN vs. $68,935 CAN) despite
the more frequent and intensive treatments [28].
In this study, we hypothesized that patients performing
home nocturnal hemodialysis would have a higher qual-
ity of life than those performing in-center hemodialysis.
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The purpose of this study was to determine whether
these quality-of-life results would lead to a superior cost
utility for home nocturnal hemodialysis compared to in-
center hemodialysis.
METHODS
Patient population
The home nocturnal hemodialysis group was formed
from patients at the Humber River Regional Hospital
in Toronto. To be eligible for this program, individuals
needed to be proficient in English, have the capacity for
self-care training, and have a life expectancy of longer
than 1 year. Either the patient or someone living in the
home needed to have sufficient dexterity, vision, and
auditory acuity to perform this type of dialysis. To be
eligible for this study, home nocturnal hemodialysis pa-
tients had to be performing the modality for at least 3
months prior to enrollment.
St. Michael’s Hospital in Toronto, Canada was se-
lected to provide patients for the control group because
it has a large in-center hemodialysis program located in
the Greater Toronto area, is university affiliated, and
had no home hemodialysis program at the time of the
study. All in-center hemodialysis patients at St. Michael’s
Hospital were screened based on the entry criteria for
the home nocturnal hemodialysis program at Humber
River Regional Hospital. The St. Michael’s Hospital he-
modialysis medical director (who was not involved with
this study) then screened this group to only those judged
to be appropriate for home hemodialysis therapy. Indi-
viduals selected were eligible to participate if they ex-
pressed an interest in home hemodialysis after descrip-
tion of the modality (although they did not need to agree
to switch modalities).
A prospective descriptive costing study was performed
from January 1, 2000 to March 1, 2001. The full method-
ology and results of this study are published elsewhere
[28]. Local and university ethics review boards approved
the protocols and consents.
Assessment of dialysis intensity
There is significant controversy regarding how best to
measure dialysis adequacy in intensively dialyzed indi-
viduals. As our hypothesis assumes a more intensive
delivery of dialysis to the home nocturnal hemodialysis
group, we measured weekly mean hours of dialysis, and
in the absence of consensus, we measured dialysis inten-
sity by calculating single session and weekly single-pool
Kt/V during a representative period of the study [29, 30].
Assessment of quality of life
Individuals were approached in a standardized man-
ner by a single interviewer to assess their quality of life.
Interviews were scheduled during a routine appointment
at the home dialysis clinic for the home nocturnal hemo-
dialysis group, and at the dialysis unit prior to treatment
for the in-center hemodialysis group. Interviews were
conducted in well-lit and quiet semiprivate offices or ex-
amination areas. A single interviewer conducted all of the
interviews. Criteria were set prospectively for delaying an
interview; specifically, hospital admission within 1 month,
current treatment with antibiotics, initiation or dose ti-
tration of a psychotropic drug within 1 month, invasive
outpatient procedure within 1 week or significant life
event within 2 months (death or sickness of a friend or
family member, change in employment status, divorce
or separation from significant other, change of address).
We used the standard gamble technique to measure
patient’s quality of life. To determine utilities by the
standard gamble, participants were given a choice of
remaining in their current state of health or accepting a
hypothetical medical treatment. If successful, this hypo-
thetical treatment would cure the renal disease, resolve
all of their medical issues, and return the patient to
the best imaginable state of health. If unsuccessful, the
hypothetical treatment would lead to immediate death.
The initial chance of death with treatment was randomly
chosen and the elicitation choices were repeated in an
iterative manner, with the chance of death varied by a
bisectional approach (in which the utilities presented
were the midpoint of the possible lowest and highest
values based on the previous responses and the bounds
of the utility scale) in order to determine the maximum
chance of immediate death that the participant would
be willing to accept for the chance of full health [31, 32].
Standard gamble utilities were elicited through a stan-
dardized interview, with the instructions for the patient
written on a prompt card for the interviewer. A com-
puter-based utility generator provided assistance (http://
individual.utoronto.ca/bayoumi/prospec). This program
visually presented the gamble probabilities in the form
of a circle, transected such that the circle consisted of
two colored areas, one representing the relative proba-
bility of immediate death, the remaining area represent-
ing the relative probability of a successful cure. Patients
were allowed to choose not to gamble.
Cost utility analysis
Once costs and benefits had been determined for an
intervention, attempts were made to determine the value
for the money that the new treatment provided. In this
study, the mean utility score as determined by the stan-
dard gamble method measured the effectiveness of dial-
ysis for each study group. A simple ratio of the mean
costs by the mean utility score provided the cost utility
for each study group relative to no treatment. A ratio
of the difference in mean costs of two therapies by the
difference in their mean utility score produced an incre-
mental cost-effectiveness ratio (ICER), which was placed
in one of the quadrants of a cost-effectiveness plane (see
Fig. 1) [33–35].
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Fig. 1. Confidence interval ellipses (5%, 50%,
and 95%) for the incremental cost-effective-
ness ratio (ICER) of home nocturnal versus
conventional in-center hemodialysis and 2500
bootstrap ICER iterations. Cost-effectiveness
ceiling  $50,000.
New therapies in the southeast quadrant are both
more effective and less costly than their alternative. They
are referred to as dominant strategies and are usually
accepted as superior to the alternative. New treatments
in the northwest corner are more expensive and less effec-
tive than conventional care, and normally rejected. New
therapies in the southwest corner (less expensive but less
effective) or the northeast corner (more effective but
more expensive) must be evaluated in more detail before
being accepted or rejected. A maximum cost-effective-
ness ceiling can be plotted on the cost-effectiveness
plane, representing a hypothetical maximum that society
would be willing to pay for an additional benefit (north-
east quadrant) or hypothetical minimum cost-savings
that society would be willing to accept for a less effective
intervention (southwest quadrant). Interventions falling
on or to the right of this line are generally considered
cost-effective, while those falling to the left are not [36].
To account for uncertainty in the ICER, we calculated
its 5%, 50%, and 95% confidence intervals and plotted
these on the standard ICER plane, with a maximum
cost-effectiveness ceiling of $50,000 [37]. To estimate the
distribution of mean costs and effectiveness, we used
the bootstrap technique. The bootstrap is a method to
estimate statistical precision using resampling (the ran-
dom selection of data from the original data set) that is
particularly useful when a mathematical formula is not
readily available. Each data point may be sampled more
than once. For each randomly drawn sample (N 2500),
we calculated mean and incremental costs and effective-
ness scores and incremental cost-effectiveness ratios and
used the resulting range of values to calculate the corre-
sponding confidence intervals [38].
Net monetary benefit
While ICERs are popular, they do not perform well
under uncertainty as calculation of their confidence in-
tervals is controversial and they are difficult to use in
regression analyses [39–44]. A newer measure known as
the net monetary benefit (NMB) addresses these con-
cerns [33]. Simplistically, the NMB is calculated by as-
signing a monetary value to the incremental benefit
achieved, and subtracting from this the incremental cost
of achieving this benefit [33]. A positive NMB implies
that the cost of a new therapy is less than the value of
the additional benefit achieved. A negative NMB implies
that an intervention should be rejected, as its costs are
higher than the value of the benefit achieved. Difficulties
arise in how to place a monetary value on a clinical
improvement. This valuation is performed by assigning
a monetary value () to a unit of effectiveness, and multi-
plying  by the net number of units of effectiveness
achieved (so that NMˆB   · E  C). Lambda rep-
resents the maximum amount that a society would be
willing to pay for the incremental improvement in out-
come (and therefore its maximum value). As the value
of  for a given clinical improvement is controversial,
we tested the full range of  from 0 to approaching
infinity.
For our study population, we constructed a NMB for
each patient, and then calculated a regression line for
the effect of type of dialysis on NMB. The regression
analysis was extended to include modeling of the effects
of any covariate with a correlation coefficient P value
0.10. The regression coefficient for a variable is the
estimate of its NMB. An acceptability curve (which rep-
resents the most accurate estimate that home nocturnal
hemodialysis is cost-effective) was generated across the
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Table 1. Demographics
In-center Home nocturnal
hemodialysis hemodialysis P value
Number 19 24
Gender (% male) 68 75 0.63
With diabetes % 11 8 0.81
With coronary
artery disease % 11 21 0.35
With peripheral
vascular disease % 5 13 0.42
With congestive heart
failure % 5 21 0.14
With post secondary
education % 69 60 0.71
Married % 54 94 0.01
Age (years) 50.19.3a 47.27.7a 0.26
Duration end-stage
renal disease years 7.16.0a 9.47.1a 0.27
a Mean standard deviation
full range of  [45]. For any value of , the probability
that home nocturnal hemodialysis is cost effective is
equal to 1 – P/2, where P is the P value for the regression
coefficient for the type of dialysis.
Statistics
Means were tested with the Wilcoxon rank-sum test.
Categoric variables were tested using the chi-squared
test. Pearson’s correlation was used for multivariate anal-
yses. Variables found to have a significant correlation
with outcome were subsequently modeled in the regres-
sion analyses, fitted using the standard least squares ap-
proach. A two-tailed significance level of 0.05 was used
for all tests. SPSS version 11.0 for Windows and JMP
version 5.0 for Macintosh were used for the statistical
analyses.
RESULTS
Population
Of the 34 patients participating in the home nocturnal
hemodialysis program during the study period, 31 met
entry criteria. Of these, two agreed to participate in the
longitudinal costing study, but declined to participate
in the quality-of-life assessment. In addition, two were
unable to schedule an interview during the study period
that did not conflict with the prespecified delay criteria,
and three were transplanted prior to being interviewed.
In total, 24 patients remained for analysis.
A total of 182 in-center hemodialysis patients were
screened, with 29 individuals passing both the home noc-
turnal hemodialysis group entry criteria and the judg-
ment of the program director. Of these, three lacked
interest in home dialysis modalities and three declined
to participate. Of these 23 individuals, two were trans-
planted prior to being interviewed, one agreed to partici-
pate in the longitudinal costing study but declined a
Table 2. Correlation of baseline variables with utility score
Correlation with
utility score
Pearson’s r P value
Male gender 0.012 0.94
Age (per year) 0.322 0.04
Duration end-stage renal disease
(per year) 0.232 0.13
Diabetes 0.154 0.33
Coronary artery disease 0.259 0.09
Peripheral vascular disease 0.250 0.11
Congestive heart failure 0.168 0.28
Married 0.104 0.58
College or university education 0.196 0.44
Dialysis modality is home nocturnal
hemodialysis 0.397 0.01
quality-of-life interview, and one was unable to schedule
an interview during the study period that did not conflict
with the delay criteria. This left 20 patients who were
interviewed. One of these patients refused on moral
grounds to gamble against death and was excluded from
the analysis.
The baseline demographics features of the two groups
were similar, with the exception of marital status, where
a greater proportion in the home nocturnal hemodialysis
were married (see Table 1). Approximately 70% of the
in-center hemodialysis group were performing self-care
dialysis at the hospital.
Dialysis intensity
The single-session Kt/V for the home nocturnal hemo-
dialysis group was 1.6  0.2, and was 1.4  .2 for the
in-center hemodialysis group. Weekly Kt/V was 9.0 for
the home nocturnal hemodialysis group, and was 4.0 for
the in-center hemodialysis group.
Quality of life
Home nocturnal hemodialysis was associated with a
higher utility than in-center hemodialysis (0.77  0.23
vs. 0.53  0.35, P  0.03). Other than home nocturnal
hemodialysis as the modality of dialysis, the only baseline
variables significantly correlated with higher utility
scores were lower age and the absence of coronary artery
disease (see Table 2). Marital status, which was different
between the groups, did not correlate with utility score
in either study group or the overall group. A regression
model was created testing the predictive effect of dialysis
modality, age, and coronary artery disease on the utility
score. In this model, higher utility scores continued to be
associated with home nocturnal hemodialysis as dialysis
modality (estimate 0.25, P  0.01), and absence of coro-
nary artery disease (estimate 0.24, P  0.04), while
younger age was no longer significant (estimate 0.007, P
0.13; model adjusted R2 0.25, P  0.01).
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Table 3. Summary of costsa
Mean annual cost
Quality of Life study subgroup Full-study group
IHD HNHD P valueb IHD HNHD
Number 19 24 23 33
Staff $22,005 $10,938 0.01 $22,056 $10,932
Direct hemodialysis materials $ 6,413 $16,669 0.01 $ 6,575 $16,587
Medications $11,546 $ 8,150 0.11 $12,029 $ 8,989
Overhead and support $12,365 $ 4,181 0.01 $12,393 $ 4,178
Physician fees $ 6,650 $ 6,650 1.00 $ 6,650 $ 6,650
Admissions and procedures $ 5,271 $ 818 0.09 $ 6,997 $ 1,173
Depreciation $ 871 $ 6,139 0.01 $ 871 $ 6,139
Lab tests and imaging $ 1,246 $ 1,594 0.04 $ 1,364 $ 1,744
Total $66,367 $55,139 0.03 $68,935 $56,394
Abbreviations are: IHD, in-center hemodialysis; HNHD, home nocturnal home dialysis.
aAll costs expressed in year 2000 Canadian dollars
bP value for comparison of IHD quality of life subgroup to HNHD quality-of-life subgroup
Table 4. Cost utility results
Group Variable Mean SD SE P value
IHD (N  19)
Cost $66,367 17,502 4015
Utility 0.527 0.347 0.08
Correlation  0.229 0.345
HNHD (N  23)
Cost $55,139 7,651 1562
Utility 0.772 0.230 0.047
Correlation  0.163 0.447
Increments
Cost $11,227 4321 0.029
Utility 0.244432 0.093 0.028
Cost utility ratios
IHD $125,845
HNHD $71,443
Incremental cost-effectiveness ratio (ICER) $45,932
Abbreviations are: IHD, in-center hemodialysis; HNHD, home nocturnal hemodialysis.
Costing study results
The subjects in this study were a subset of our previous
costing study, and the results specific to this group were
similar to those results (Table 3). Total health care costs
for the home nocturnal hemodialysis group compared
to the in-center hemodialysis group were significantly
lower ($55,139 $7651 vs. $66,367 $17,502, P 0.03).
Specifically, staffing and overhead were significantly less
costly for home nocturnal hemodialysis. In contrast, di-
rect hemodialysis materials, depreciation, laboratory
tests, and imaging were all significantly more expensive
for home nocturnal hemodialysis.
Cost utility analysis
Coupled with the lower costs for home nocturnal he-
modialysis, the cost utility for home nocturnal hemodial-
ysis was $71,443/quality-adjusted life-year (QALY),
while for in-center hemodialysis it was $125,845/QALY.
Home nocturnal hemodialysis was the dominant strat-
egy, with an ICER of $45,932 (Table 4). Figure 1 plots
this result, along with 5%, 50%, and 95% confidence inter-
val ellipses and with the ICER generated by 2500 bootstrap
iterations. From the bootstrap data, the 95% confidence
interval of the ICER was $13,976 to $142,998.
Net monetary benefit
The NMB of home nocturnal hemodialysis ranged
from $11,227 (  $0) to $35,669 (  $100,000) (Table
5, dispersion of individual patient values, Fig. 2). When
a multivariate regression model was used, including age
and presence of coronary artery disease as covariates
(plus interactions with dialysis modality), the NMB of
home nocturnal hemodialysis ranged from $11,258 ( 
$0, P  0.010; adjusted R2 0.115, P  0.05) to $35,819
(  $100,000, P  0.001; adjusted R2 0.20, P  0.001)
(Table 5). As demonstrated by the acceptability curves,
this data suggest that the probability that home nocturnal
hemodialysis is cost-effective exceeds 99% across all val-
ues for , even when adjusted for significant covariates
(Fig. 3).
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Table 5. Net monetary benefit (NMB) estimates as a increases
  $0   $50,000   $100,000 →∞b
NMBSE (P value) NMBSE (P value) NMBSE (P value) (P value)
Calculated NMB
(NMˆB   · E  C)
HNHD $11,227 (0.01) $23,448 (0.01) $35,669 (0.01) (0.006)
NMB by regression with covariates
(age and presence of CAD)
Explanatory variable
HNHD $11,258$4158 (0.01) $23,539$6421 (0.01) $35,819$10,054 (0.001) (0.006)
Age (per year) $111$247 (0.66) $504$382 (0.19) $898$598 (0.141) (0.127)
Presence of CAD $3,473$5553 (0.54) $15,321$8575 (0.08) $27,170$13,428 (0.050) (0.043)
Regression model
R2 (adjusted) 0.115 0.288 0.298 0.248
Probability  F (0.05) (0.01) (0.01) (0.01)
Abbreviations are: HNHD, home nocturnal hemodialysis; CAD, history of coronary artery disease.
a represents the societal maximum willingness-to-pay for a benefit
b As  approaches ∞, the P value for the explanatory variable approaches the P value of the standard gamble score
Fig. 2. Net monetary benefit (NMB) individual patient dispersion with
 $100,000. Abbreviations are: IHD, in-center hemodialysis; HNHD,
home nocturnal hemodialysis.
DISCUSSION
We assessed whether patients performing home noc-
turnal hemodialysis have a higher quality of life than similar
patients receiving hemodialysis at an in-center unit. These
results are the first utility scores from individuals inten-
sively dialyzed by the home nocturnal hemodialysis tech-
nique, and support the hypothesis that home nocturnal
hemodialysis is associated with a significantly higher quality
of life. Indeed, the utility scores seen here for the home
nocturnal hemodialysis group are similar to the scores
described in those with a successful kidney transplant [10]
and agree with anecdotal reports of individuals perform-
ing home nocturnal hemodialysis who remove themselves
Fig. 3. Acceptability curve for home nocturnal hemodialysis.
from the transplant waiting list, presumably because they
do not anticipate that transplant will further improve
their quality of life. On a disturbing note, the convention-
ally dialyzed individuals had similar utility scores to those
seen historically, showing no evidence of improvement
in quality of life over time. This is despite the fact that our
conventional group was demographically skewed toward
individuals expected to have a higher quality of life than
many in-center hemodialysis patients (younger age, higher
functional status, lower comorbidities).
We attempted to study patients who were as similar
as possible. Our in-center hemodialysis group was com-
posed of those who were demographically similar to the
home nocturnal hemodialysis group, were interested in
and thought to be capable of performing home hemodial-
ysis, but were unable due to the lack of a home program
at their hospital. Individuals in the in-center hemodialy-
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sis control group were less likely to be married; however,
marital status did not correlate with quality of life in this
study. Older age and the presence of coronary artery
disease were associated with a reduced quality of life in
this study. Home nocturnal hemodialysis was strongly
associated with a greater NMB, even after adjustment
for these factors. However, it is possible that people
who choose to do home hemodialysis have immeasurable
characteristics that are associated with higher quality of
life independent of the form that their home dialysis
takes, thus confounding these results.
Although both groups were demographically similar,
neither was similar to the “average” hemodialysis pa-
tient. In this study, participants in both groups were in
general younger, had less diabetes and cardiovascular
disease, and had been on dialysis for longer than demo-
graphically typical patients from most centers [46]. This
may bias the utility scores toward higher values for both
groups.
Dialysis patients may have temporary events occur
that can cause considerable distress. As our sample size
was small, we attempted to perform our interviews on
a typical day and delayed interviews in the event of
recent experiences that could significantly lower quality
of life. This has intentionally biased our utilities toward
higher scores than might be seen in a cross-sectional study
where interviews were conducted regardless of the pa-
tient’s current situation. We measured utilities with the
standard gamble technique, a commonly used method
to measure quality of life in health economics. In contrast
to instruments such as the SF-36 that measure health
status, the standard gamble and other utility methods
reflect an individual’s preferences for health states. Be-
cause people with similar health status may feel differ-
ently about how desirable their health condition is, utility
measures tend to have greater variability than psycho-
metric instruments and the correlation between the two
techniques has been, at best, modest. Controversy per-
sists regarding the optimal choice of method to measure
utility, as all methods are susceptible to biases [47]. Nev-
ertheless, the size and direction of effect in our study
are of such magnitude and consistency that it is unlikely
that correcting for operative biases would significantly
change our results.
As our study examined prevalent patients only, our
results do not answer whether home nocturnal hemodial-
ysis will improve quality of life in patients switched from
in-center hemodialysis. Future research should prospec-
tively measure quality of life in patients as they move
from in-center hemodialysis to home nocturnal hemodi-
alysis.
The home nocturnal hemodialysis program at the
Humber River Regional Hospital is the world’s first and
largest program. Despite this, the sample size is small,
and other centers with home nocturnal hemodialysis pro-
grams will need to confirm these results to ensure that
this is a modality effect and not related to an unmeasured
selection bias. Prospective studies of patients before and
after changing modalities will also be necessary to sup-
port the conclusion that home nocturnal hemodialysis
improves quality of life. In addition, the costs that we
describe for home nocturnal hemodialysis are from a
large and established program. New programs or small
programs may not enjoy some of the economies of scale
as seen in the Humber River Regional Hospital program.
Previous work by our research group found that heath
care costs were lower for patients performing home noc-
turnal hemodialysis. This study has demonstrated that
home nocturnal hemodialysis is the dominant strategy,
both lowering costs and improving quality of life. Dialysis
programs should consider offering home nocturnal he-
modialysis to appropriate patients in hope of seeing bet-
ter quality of life as well as reduced health care costs.
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